Legend Biotech began to validate its in vivo CAR T approach with early data from an investigator-initiated study in lymphoma. Initial results reported by the company showed tumor responses across the first cohort and were positioned as a potential alternative to traditional ex vivo manufacturing. The early readout helped lift investor sentiment around Legend’s next steps, with emphasis on practicality and potential scalability of “in vivo” engineering, where CAR T components are delivered and assembled inside the body rather than manufactured outside. The company’s performance stands out against a backdrop of intense competition in CAR T, where manufacturing complexity and time-to-treatment remain core bottlenecks.